Free tool
FAERS Monitor: Nexium 24hr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207920 or its brand name (Nexium 24hr, Esomeprazole Magnesium). Reports on generic versions are filed under their own applications.
Reports
42,318
Serious
34,306
81% of reports
Hospitalization
7,594
Death reported
3,791
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chronic kidney disease19,478
- acute kidney injury9,970
- renal failure7,889
- renal injury6,117
- end stage renal disease6,040
- drug ineffective2,746
- tubulointerstitial nephritis2,445
- gastrooesophageal reflux disease2,274
- nausea1,822
- pain1,748
- death1,717
- off label use1,544
- headache1,524
- diarrhoea1,492
- nephrogenic anaemia1,382
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 72 |
| 2006 | 203 |
| 2007 | 442 |
| 2008 | 772 |
| 2009 | 488 |
| 2010 | 391 |
| 2011 | 385 |
| 2012 | 303 |
| 2013 | 129 |
| 2014 | 741 |
| 2015 | 1,282 |
| 2016 | 1,506 |
| 2017 | 1,349 |
| 2018 | 11,308 |
| 2019 | 10,657 |
| 2020 | 2,438 |
| 2021 | 2,685 |
| 2022 | 1,687 |
| 2023 | 1,407 |
| 2024 | 1,437 |
| 2025 | 1,558 |
| 2026 | 1,032 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,011,841 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| end stage renal diseaseSignal | 6,040 | 245.5 | 238.4 | 984,787 |
| nephrogenic anaemiaSignal | 1,382 | 210.8 | 198.1 | 202,473 |
| chronic kidney diseaseSignal | 19,478 | 170.9 | 168.7 | 2,456,607 |
| renal injurySignal | 6,117 | 128.6 | 125.2 | 615,751 |
| tubulointerstitial nephritisSignal | 2,445 | 74.4 | 71.4 | 154,062 |
| acute kidney injurySignal | 9,970 | 34.6 | 34.0 | 306,007 |
| renal failureSignal | 7,889 | 31.3 | 30.7 | 219,217 |
| gastrooesophageal reflux diseaseSignal | 2,274 | 14.4 | 13.8 | 27,688 |
| pain | 1,748 | 1.4 | 1.4 | 219 |
| headache | 1,524 | 1.2 | 1.2 | 56 |
| diarrhoea | 1,492 | 1.1 | 1.1 | 30 |
| nausea | 1,822 | 1.1 | 1.1 | 34 |
| drug ineffective | 2,746 | 1.0 | 1.0 | 4 |
| death | 1,717 | 1.0 | 0.9 | 0 |
| off label use | 1,544 | 0.9 | 0.8 | 28 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.